383 S. Colorow Drive
Salt Lake City
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to radically improve the lives of patients and industrialize drug discovery. Our team is working to solve some of the hardest, most meaningful problems facing human health today. Come join us in our mission to decode biology to radically improve lives, while doing the most impactful work of your life.
Working @ Recursion
50 articles with Recursion
Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.
1/11/2022According to recent BioSpace research, 78% of employers indicated that the number of open roles will be in increasing for 2022. More positions open, the better the odds of finding a new job.
12/21/2021The year kicked off with a bang as multiple companies raced to a public listing.
Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology
Recursion today announced a transformational collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Genentech, a member of the Roche Group.
Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.
12/3/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments
Recursion, a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, announced a deepening of its neuroscience expertise with key hires in human induced pluripotent stem cell biology, translational neuroscience and clinical development.
Recursion Pharmaceuticals today reported business updates and financial results for its third quarter ending September 30, 2021.
Recursion today reported financial results and business updates for its second quarter ending June 30, 2021.
Lux Capital, Mubadala Capital, Obvious Ventures, and DCVC among founding group supporting underrepresented founders building next-generation healthcare companies
Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results for the first quarter of 2021 and provided business updates.
Recursion Pharmaceuticals, Inc. ("Recursion" or "we") announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to purchase 3,636,363 additional shares of its Class A common stock, at a price to the public of $18.00 per share.
4/21/2021Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
Recursion Pharmaceuticals, Inc. announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share.
After initially indicating it intended to raise $100 million in its Nasdaq debut, the Salt Lake City-based company will now look at bringing in approximately $306 million.
3/24/2021It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
This week, four companies set sights on listing their shares on the stock market in hopes of raising significant funds to support the development of their pipelines and businesses.
Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases
Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster
Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome
Recursion , a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to gain rights to TAK-733, a clinical-stage MEK inhibitor, and develop it for the treatment of a hereditary cancer syndrome and related areas of oncology. “TAK-733 is a great example of the power of our approach to decode challenging
3/27/2020Pharma and life sciences companies from across the globe provide updates on their pipelines and business.